BHVN

NYSE 已收盘

Biohaven

13.65 USD
▲+0.75+5.81%
盘后 13.60 -0.37%
2026-11-19
市值
$1.87B
市盈率
—
EPS
-3.81
股息率
—
52 周区间
8.03 – 18.24
成交量
3.26M
Beta
3.13
目标价
25.13
52W 低 8.0352W 高 18.24
价格走势

公司简介

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim...

关联新闻